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Abstract
Purpose After completing treatment, cancer survivors may
suffer from a multitude of physical and mental health impair-
ments, resulting in compromised quality of life. This explor-
atory study investigated whether two mind–body interventions,
i.e., Mind–Body Bridging (MBB) and Mindfulness Meditation
(MM), could improve posttreatment cancer survivors’ self-
reported sleep disturbance and comorbid symptoms, as com-
pared to sleep hygiene education (SHE) as an active control.
Methods This randomized controlled trial examined 57 can-
cer survivors with clinically significant self-reported sleep
disturbance, randomly assigned to receive MBB, MM, or
SHE. All interventions were conducted in three sessions, once
per week. Patient-reported outcomes were assessed via the
Medical Outcomes Study Sleep Scale and other indicators of
psychosocial functioning relevant to quality of life, stress,
depression, mindfulness, self-compassion, and well-being.
Results Mixed effects model analysis revealed that mean
sleep disturbance symptoms in the MBB (p=.0029) and
MM (p=.0499) groups were lower than in the SHE group,
indicating that both mind–body interventions improved
sleep. In addition, compared with the SHE group, the
MBB group showed reductions in self-reported depression
symptoms (p=.040) and improvements in overall levels of
mindfulness (p=.018), self-compassion (p=.028), and well-
being (p=.019) at postintervention.
Conclusions This study provides preliminary evidence that
brief sleep-focused MBB and MM are promising interven-
tions for sleep disturbance in cancer survivors. Integrating
MBB or MM into posttreatment supportive plans should
enhance care of cancer survivors with sleep disturbance.
Because MBB produced additional secondary benefits,
MBB may serve as a promising multipurpose intervention
for posttreatment cancer survivors suffering from sleep dis-
turbance and other comorbid symptoms.
Implications for Cancer Survivors Two brief sleep-focused
mind–body interventions investigated in the study were
effective in reducing sleep disturbance and one of them
further improved other psychosocial aspects of the cancer
survivors’ life. Management of sleep problems in survivors
is a high priority issue that demands more attention in cancer
survivorship.
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Introduction
The experience of cancer and its treatment can take a heavy
toll on cancer patients, who, following treatment, may
http://clinicaltrials.gov/ct2/show/NCT00935376
ClinicalTrials.gov Identifier: NCT00935376
Y. Nakamura (*) :D. L. Lipschitz :R. Kuhn :G. W. Donaldson
Utah Center for Exploring Mind–Body Interactions (UCEMBI),
Pain Research Center, Department of Anesthesiology, School of
Medicine, University of Utah, 615 Arapeen Drive, Suite 200,
Salt Lake City, UT 84108, USA
e-mail: yoshi.nakamura@utah.edu
Y. Nakamura :D. L. Lipschitz : R. Kuhn :G. W. Donaldson
Pain Research Center, Department of Anesthesiology, School of
Medicine, University of Utah, Salt Lake City, UT, USA
A. Y. Kinney
Cancer Control and Population Sciences Program, the Huntsman
Cancer Institute, and Department of Internal Medicine, School of
Medicine, University of Utah, Salt Lake City, UT, USA
J Cancer Surviv (2013) 7:165–182
DOI 10.1007/s11764-012-0252-8
continue to suffer from many physical and psychological
concerns. Fatigue, depression, cognitive impairment, and
sleep disturbance are found to be related to compromised
quality of life (QOL), decreased treatment adherence, and
increased cancer-related morbidity [1]. In particular, sleep
disturbance has been recognized as a persisting problem that
is not always addressed effectively in posttreatment care
[2–4]. Cancer survivors need better options for alleviating
sleep disturbance and improving health-related QOL.
Sleep disturbance often includes reduced sleep efficiency,
prolonged latency to falling asleep, and increased wake time
during the night. Recent data indicate that a high percentage
(19–30 %) of cancer patients report sleep problems [5, 6].
Almost 20 % of posttreatment breast cancer patients
reported more than 6 months of chronic insomnia [1], con-
tinuing for several years after diagnosis in a large number of
breast cancer patients [7]. Furthermore, insomnia is a pow-
erful predictor of cancer-related fatigue [1]. Standard phar-
macological treatment options for sleep problems include
medications such as benzodiazepines and benzodiazepine
receptor agonists [8]. While these may provide some symp-
tom relief, tolerance may develop, and long-term use can
cause fragmented sleep patterns and overreliance on medi-
cation to facilitate sleep onset [8]. Furthermore, medication
side effects may be troublesome.
Basic and clinical science evidence supports the premise
that mind–body interventions can enhance patients’ healing
and recovery, and increase well-being and autonomy [9].
What we term mindfulness-based interventions (MBIs) are
mind–body interventions that focus on the power of mental
training in regulating health conditions [10]. MBIs utilize
mental training to facilitate awareness, attention, intention,
and attitude [11]. In our view, MBIs comprise interventions
such as Mindfulness-Based Stress Reduction (MBSR) [12,
13], Mindfulness-Based Cognitive Therapy (MBCT) [14,
15], and a recent addition, Mind–Body Bridging (MBB)
[16]. These MBIs may help treat and manage conditions
such as cancer, chronic pain, sleep disturbance, and depres-
sion (see Shapiro and Carlson [17] for an overview).
Several recent studies investigated the efficacy and utility
of MBSR in managing persisting symptoms in cancer
patients and posttreatment survivors [7, 18–25]. The find-
ings from these studies are positive and promising, suggest-
ing that MBSR is effective for managing persisting
symptoms in breast and prostate cancer patients. More re-
cently, a number of systematic reviews and meta-analyses
[26–29] of MBSR and MBI for cancer patients and survi-
vors have appeared, further documenting that MBSR in
particular and MBI in general are effective in controlling
symptoms and improving QOL in cancer patients and
survivors.
Nonetheless, MBSR’s efficacy in specifically improving
sleep remains to be demonstrated conclusively. In a
systematic review of clinical studies of MBSR targeting
sleep [30], seven studies were identified. The review
reported that the lack of standardized outcome measures
precludes pooling of results for quantitative data analysis
and that sleep report measures varied (standardized scales,
single item, and sleep diaries). Four studies (all uncon-
trolled) found that MBSR significantly improved measures
of sleep quality or duration, while three studies found no
statistically significant difference between treatment and
control conditions.
Another recent randomized controlled trial study directly
compared MBSR against a standard pharmacotherapy treat-
ment for chronic primary insomnia [31]. The authors
reported that MBSR improved sleep onset latency measured
by actigraphy (8.9 min) as well as large significant improve-
ments measured by various self-report sleep measures. Britton
and her colleagues [32] examined whether mindfulness med-
itation (MM) was associated with changes in objectively
measured polysomnographic (PSG) sleep profiles and wheth-
er changes in PSG sleep were related to subjectively reported
changes in sleep and depression. They found that according to
PSG sleep data, mindfulness meditation practice was associ-
ated with several indices of increased cortical arousal, includ-
ing more awakenings and stage 1 sleep and less slow-wave
sleep relative to wait-list controls, in proportion to amount of
meditation practice. This study underscores potential complex
relationships between meditation practice and objective/sub-
jective sleep measures.
We recently evaluated MBB, in a prospective randomized
controlled trial with veterans who suffered from clinically
significant self-reported sleep disturbance [33]. The results
from our study supported the efficacy of brief sleep-focused
MBB in improving not only sleep disturbance but also self-
reported comorbid posttraumatic stress disorder (PTSD)
symptoms in veterans. Clinicians working at the VA Salt Lake
City Health Care System have used MBB in their clinical
practice dealing with a variety of mental health conditions
and reported anecdotally that MBB seemed effective for man-
aging conditions ranging from PTSD, depression, substance
abuse to sleep disturbance, as well as for improving health-
related quality of life in patients with wide ranging conditions.
In light of this preliminary evidence reported above, we
reasoned that MBB might be useful in managing sleep and
other comorbid symptoms in cancer survivors. We also
wanted to examine the efficacy of MBB together with
another MBI such as Mindfulness Meditation (MM), which
is perhaps one of the most critical components of MBSR
and other MBIs (see Chiesa and Serretti [34] for reviews
of mindfulness meditation and its benefits). As an active
control condition, we included Sleep Hygiene Education
(SHE).
Thus, our exploratory study with cancer survivors
employed a three-armed randomized controlled parallel
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group study design. MBB and MM have both similarities
and differences. Both MM and MBB highlight awareness
practices as core skills in the programs. However, MM
obviously includes meditation practice, while MBB does
not. MBB is focused on developing experiential bridging
skills and utilizing Mind–Body Mapping (an exercise
designed to make explicit people’s often implicit “require-
ments” of situations; see [35] for more details), while MM
does not explicitly include such an exercise for identifying
requirements. Given these shared features and key differ-
ences, comparison of the two interventions may offer useful
pilot data for clarifying the nature of potential therapeutic
benefits from these two programs. On the basis of clini-
cians’ anecdotal reports supporting potential usefulness of
MBB for wide-ranging conditions, we also wanted to inves-
tigate the potential impacts of these sleep-focused MBIs on
common comorbid symptoms and psychosocial indicators.
Thus, our study included several secondary outcome meas-
ures, as a means of more fully understanding the new
intervention programs’ potential impacts [36].
We hypothesized that MBB and MM would improve
self-reported sleep problems and reduce other behavioral
or psychological symptoms persisting into the postcancer
treatment period. More specifically, we hypothesized that
MBB and MM would be more effective than SHE in man-
aging sleep problems in cancer survivors. The study targeted
cancer survivors without requiring specific types of cancer
for at least two reasons. First, health-related QOL compro-
mised by sleep disturbance and other behavioral or psycho-
logical symptoms may be more or less comparable across
subjects with different cancer types [37]. Second, some level
of symptom burden in cancer survivorship is highly preva-
lent across different types of cancer [38]. Thus, this study
served as an exploratory pilot study for establishing the
broad efficacy of MBB and MM for supportive care of
cancer survivors, by exploring potential impacts of these
interventions on sleep (the primary endpoint) and several




We recruited participants from various cancer clinics
(Huntsman Cancer Institute, University of Utah), a cancer
support center (Cancer Wellness House), and cancer support
events (Survivors at the Summit), and through flyers and
newspaper advertisements. Participants were male and fe-
male, 18–75 years old. We conducted the study from July
2009 through April 2010 at Cancer Wellness House, a
nonprofit organization offering support for those living with
cancer, surviving cancer, and their family members. The
Institutional Review Board at the University of Utah ap-
proved the study protocol.
Inclusion criteria
Since this was an exploratory study, we included survivors
of any type of cancer. Cancer survivor was defined as any
patient who had completed active cancer treatment. To
qualify, participants must have completed active cancer
treatment (surgery, chemotherapy, or radiation therapy) at
least 3 months prior to attending the first study session.
However, they could be on adjuvant hormone therapy
(e.g., Tamoxifen, Lupron, or aromatase inhibitors), sleep
medication, or other medications (exceptions listed in exclu-
sion criteria, below). Participants exhibited self-reported sleep
disturbance, assessed by a validated sleep questionnaire, the
Medical Outcomes Study Sleep Scale (MOS-SS) [39]; to be
eligible to participate in the study, participants needed to score
at least 35 on the MOS-SS Sleep Problems Index II subscale
(SPI-II). Scores of 35 and above suggest a high probability of
a clinically significant sleep disturbance. No specialized or
medical diagnosis of insomnia was undertaken or required.
Any type of sleep disturbance or problem was included.
Participants spoke and understood English.
Exclusion criteria
The following criteria resulted in exclusion from the study:
(1) any underlying severe or untreated psychopathology or
psychiatric illness (e.g., schizophrenia); (2) cognitive im-
pairment; (3) neurologic disorder; (4) dementia; (5) taking
antipsychotic medication, immunosuppressants and/or corti-
costeroids; (6) having a metastatic disease; and (7) previous
exposure to MBB or MM or MBSR or MBCT.
Study design
We conducted a prospective, randomized study investigating
the effects of the three short-term interventions on sleep in
cancer survivors. All interventions consisted of three 2-
h sessions, provided once a week for three consecutive weeks.
Using computer-generated numbers, we randomly assigned
participants to either one of the two interventions selected for
each treatment cycle out of the three intervention programs
investigated in the study: the SHE program (active control),
MBB, and MM. The number of consented participants
available at a specific time point determined the size of
the groups in each cycle. Since the interventions were
held at the same location, we assigned each participant
to one of the interventions when they arrived for their
first class. We randomized participants in randomly gen-
erated blocks of two interventions per cycle (except for the
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last cycle), maintaining balance of assignments over the
seven cycles.
Interventions
Sleep hygiene education program
The control intervention was SHE, in which participants
received educational classes informing them how to change
their habits to improve sleep, and what to do if they had
concerns about sleep quality. The program was based on
the Huntsman Online Patient Education (HOPE) Guide,
“Insomnia: patient symptom information” (http://www.
hopeguide.org/hope/). Topics included (but were not limited
to): “Why would I have insomnia?” (caused by some medi-
cations, stress, anxiety, or depression, pain), “When should I
call my doctor?” (worries or concerns about sleeping or have
questions about insomnia), “What can I do to get a better
night’s sleep?” (diet, exercise, supportive care, getting ready
to sleep), “What should I avoid to get a better night’s sleep?”
(tips on behaviors that can negatively influence sleep quality),
and “What should I know about medicine for sleep problems?
” (side-effects and mechanisms of sleep medications and other
medications affecting sleep).
After the SHE instructor explained each HOPE recom-
mendation, participants had an opportunity to ask questions
and discuss their sleep issues. Participants were encouraged
to follow the SHE recommendations on a daily basis. SHE
classes were presented by a licensed clinical social worker
with extensive expertise in cancer supportive care.
Mindfulness Meditation program
MM was based on MBSR [40], which is a longer program
teaching awareness and mindfulness skills, including basic
meditation practice and yoga. MBSR was developed and
implemented to treat persistent and elevated levels of stress,
sleep disturbance, and other behavioral problems in both
healthy subjects and those with clinical illnesses (for a meta-
analysis review, see Grossman et al. [41]). Mindfulness may
be defined as paying attention in a particular way, on pur-
pose, in the present moment, and nonjudgmentally [40]. The
goal of MBSR is to provide participants with experiential
tools and mindfulness practices that help them become more
aware of how the mind (including thoughts, emotions and
physical sensations) works and relates to external environ-
ments. MBSR programs focusing on sleep symptoms pre-
viously have used a 6-week long format [7, 21], twice as
long as our MM program. It should be noted here that the
MM program was not intended to cover all the elements
included in the standard MBSR program.
To create a 3-week MM program for our study, we
specifically and selectively focused on various forms of
mindfulness meditation (e.g., sitting, walking, and body
scan). Our MM course included the following: during mind-
fulness meditation practices at weekly group meetings, fun-
damental mindfulness meditation skills (breath awareness,
awareness of thoughts and emotions), body scans, walking
meditation, and forgiveness meditation were reviewed and
taught. Group members initially were asked to introduce
themselves and include, if they wished, something about
their cancer experience and sleep difficulties. Thereafter,
they were asked to talk about their cancer only as related
to what issues came up during the practices or processes
presented. Attention was given to how this differentiates the
MM program from a traditional cancer support group. Time
was devoted in sessions 2 and 3 to group discussions
concerning the implementation of moment-to-moment
awareness in the participants’ lives, allowing for the oppor-
tunity for them to learn from one another about how to
integrate mindfulness throughout the day. Discussion of
issues concerning sleep was focused on the participants’
experience related to sleep disturbance, having utilized the
processes associated with mindfulness throughout the day.
Home practice assignments were at each individual’s
discretion, given that participants were not told in advance
that there would be extensive homework assignments (as
would be the case in MBSR programs). Participants were
free to utilize the MBSR meditation CDs covering body
scan and breath meditation, as their schedules allowed,
noting that some practice would facilitate a more successful
outcome. (The MM program did not involve any focus on
yoga practice, and participants were instructed to work with
their health care provider/physical therapist prior to any
utilization of the MBSR yoga CDs.) Participants were also
assigned a writing exercise wherein they were asked to write
about a concern that was causing them to feel stressed, with
a focus on including emotional content and expressing
themselves as fully as possible. Handouts for the course
included the CDs for mindfulness meditation, a copy of
the book, Full catastrophe living, a printout on “The practice
of mindfulness” taken from the book, and stress reduction tips.
MM was taught by a licensed clinical social worker/oncology
social worker who is an experiencedMBSR instructor and has
years of meditation experience.
Mind–Body Bridging program
A summary of MBB appears in a few other publications
discussing this novel program [33, 35]. Briefly, MBB is a
mind–body intervention that may be beneficial for a wide
range of mental and physical health problems. MBB teaches
awareness skills that help individuals recognize and become
aware of a dysfunctional mind–body state characterized by
heightened self-centeredness, as indicated by ruminative
thoughts, involuntary constriction of awareness, body tension,
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and impaired mental or physical functioning. MBB also
teaches mind–body “mapping” exercises, which are designed
to reveal thought patterns known as “requirements” and to
link them to bodily states experienced at the time when
“requirements” are identified. Requirements are expectations
about how people and the world should be at particular
moments (an example of a requirement is “I should cope with
my cancer more effectively” or “I should not have any symp-
toms”). Identification of “requirements” is the key component
of the MBB program. However, unlike cognitive behavioral
therapy-based programs, MBB does not strive to identify
maladaptive thought patterns and does not attempt to change
them into more adaptive ones. When requirements are not
fulfilled, people may develop ruminative storylines that in
turn may lead to dysfunctional mind–body states. Using
awareness practices and defusing requirements, over time
and with practice, MBB practitioners learn to expand their
awareness, deal more effectively with daily life’s challenges,
and foster more balanced, harmonious mind–body states. In
this way, MBB carries awareness practices one critical step
further by addressing the underlying cause of the resistances
to clarity, i.e., mental afflictions caused by an individual’s
fixed idea of who she/he is, known as the “Identity System”
or “I-System” inMBB teaching language.When requirements
are not satisfied, the I-System gets activated and produces a
self-centered mind–body state. When this happens, it can
impede a person’s natural functioning. Increased awareness
of the I-System may contribute to MBB’s therapeutic useful-
ness. MBB techniques are easy to learn and benefits may
accrue rapidly (see Tollefson et al. [35] for more detailed
descriptions of a general MBB program). In our previous
study [33], as compared with SHE, MBB significantly re-
duced sleep disturbance in veterans after two weekly sessions.
For the present study, the third session was added to the
program used in the previous study in order to be responsive
to common issues characteristic of cancer survivors.
The study MBB training covered: identifying what, from
MBB’s perspective, may be a critical component in persistent
sleep problems; learning to use MBB tools, such as exercises
to reduce daytime stress; increasing self-awareness; address-
ing sleep issues pertinent to cancer survivors; and practicing
MBB on a daily basis. The MBB training program was taught
by a licensed clinical social worker who is a certified MBB
instructor.
Adherence to programs
Participants in all groups were asked to apply the techniques
and the information they learned during the study and the 2-
month period leading to the follow-up assessment. In the
MM group, they were encouraged to listen to CDs and read
portions of the two books used in the course. In the MBB
group, they were asked to complete mind–body map
exercises from the textbook used. In the SHE group, they
were asked to review periodically what they learned from
the SHE program.
Study procedures
Potential participants contacting the study team completed a
screening questionnaire, which covered sleep patterns, de-
mographics, cancer history (type of cancer and treatment),
medical history, and medications/supplements used. If a
person passed this screening phase, the study team contacted
that person’s health care provider (with the participant’s
signed consent) to verify that their mental health and cancer
treatment status did not preclude participation in the study.
Participants agreed to participate in the study by signing an
informed consent form.
Participants were assessed for study outcome meas-
ures using self-report questionnaires, at prerandomization
(baseline), at postintervention, and at 2-month follow-up.
They also completed exit surveys at postintervention and
follow-up.We invited subjects who did not complete the study
to participate in the follow-up assessment.
Outcome measures
Primary measures
Medical Outcomes Study Sleep Scale [39] The MOS-SS is a
validated 12-item scale providing an index of sleep prob-
lems over the past week and incorporating six subscales: (1)
sleep disturbance, (2) sleep adequacy, (3) daytime somno-
lence, (4) snoring, (5) waking up short of breath with a
headache, and (6) quantity of sleep. Two additional sub-
scales evaluate composite sleep problems based on the
above subscales: Sleep Problems Indexes I and II (SPI-I
and SPI-II). SPI-II was the main inclusion and outcome
measure used in this study, as it is a composite score reflecting
sleep disturbance, sleep adequacy and somnolence.
The MOS-SS is similar to the Pittsburgh Sleep Quality
Index (PSQI) developed around the same time, but PSQI is
not validated for a 1-week time frame and thus was judged
to be suboptimal for our study.
We assessed sleep, using MOS-SS at six time points,
including: two baselines (1) at least 1 week before the
interventions started and (2) immediately prior to the begin-
ning of the first intervention session and four assessments at
post randomization (3) at week2 (before the second inter-
vention session), (4) at week3 (before the third intervention
session), (5) postintervention, and (6) follow-up.
MOS-SS has been employed to investigate disrupted
sleep in a variety of cancer populations [42, 43]. In the
present study, Cronbach’s alpha coefficient for SPI-II was
.72, which is comparable to that reported by Hays et al. [39].
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The following primary and secondary measures described
below were assessed at three time points: (1) pre (baseline),
(2) post, and (3) follow-up.
Functional Assessment of Cancer Therapy—General
[44] Since we are interested in how the mind–body interven-
tions may help cancer survivors, we assessed the programs’
relative efficacy using Functional Assessment of Cancer Ther-
apy—General (FACT-G), a nonspecific cancer-based measure
of QOL/well-being. FACT-G includes 27 items and encom-
passes 4 different indices of well-being: physical, social/fam-
ily, emotional, and functional well-being [44], and it has been
used to evaluate cancer-related QOL in many studies [45–49].
In the present study, Cronbach’s alpha coefficient for FACT-G
total score was .92.
Perceived Stress Scale [50, 51] The Perceived Stress Scale
(PSS) measures the degree to which participants consider
situations to be stressful, based on the extent to which they
perceive their lives to be unpredictable, uncontrollable, or
overloaded. We used the 10-item version, which has maxi-
mum reliability. The PSS has been previously used to evaluate
impacts of an MBSR program in cancer survivors [52]. In the
present study, Cronbach’s alpha coefficient for PSS total score
was .92.
Secondary measures
Center for Epidemiological Studies-Depression Scale [53]
The Center for Epidemiological Studies-Depression Scale
(CES-D) comprises 20 items and is one of the most common
screening tests for the presence of depressive symptoms.
CES-D has been used in many different studies of adult
cancer survivors [48, 49, 54, 55]. In the present study,
Cronbach’s alpha coefficient for CES-D total score was .92.
Impact of event scale [56, 57] The Impact of event scale
(IES) is a standardized self-report 15-item questionnaire that
examines intrusive and avoidant thoughts and actions that a
person experiences related to cancer. The IES has been used
to assess impacts of an MBSR program in cancer survivors
[52] and in other studies to investigate quality of life in long-
term adult cancer survivors [45, 48]. In the current study,
Cronbach’s alpha coefficient for IES total score was .91.
Five-Facet Mindfulness Questionnaire [58] The Five-Facet
Mindfulness Questionnaire (FF-MQ) includes 39 items and
assesses five distinct, interpretable facets of mindfulness,
including (1) observing, (2) describing, (3) acting with
awareness, (4) nonjudging of inner experience, and (5) non-
reactivity to inner experience. We computed a total mind-
fulness score, which we used to analyze the degree to which
the interventions cultivated mindfulness in the participating
cancer survivors. The FF-MQ was used in a study investi-
gating the effects of an MBSR program in posttreatment
cancer patients [52]. In the current study, Cronbach’s alpha
coefficient for FF-MQ total score was .92.
Self-Compassion Scale [59] This scale comprises 26 items
and is used to measure self-compassion, an emotionally pos-
itive attitude that can protect against the negative consequen-
ces of self-judgment, isolation, and rumination (such as in
depression). Self-compassion entails three main components:
(1) self-kindness (being kind and understanding toward
oneself in instances of pain or failure, rather than being harsh-
ly self-critical); (2) common humanity (perceiving one’s expe-
riences as part of the larger human experience, rather than
seeing them as separating and isolating); and (3) mindfulness
(holding painful thoughts and feelings in balanced awareness,
rather than over-identifying with them). The Self-Compassion
Scale (SCS) was recently used in an MBSR study [60], and a
subscale of the SCS was used in breast cancer survivors to
understand the role of self-kindness [61]. In the current study,
Cronbach’s alpha coefficient for the total score was .96.
WHO Well-Being Index [62] Study participants filled out
the WBI, which was developed and validated by the World
Health Organization Collaborating Centre in Mental Health.
This five-item index covers positive and negative aspects of
emotional functioning [63]. In the current study, Cronbach’s
alpha coefficient for the total score was .88.
Positive and Negative Affect Schedule [64] Emotional ex-
perience can be reliably divided into the two categories of
positive affect (PA) and negative affect (NA), which are
consistent across many different dimensions (populations,
languages, cultures, time frames, and response formats)
[65]. A validated self-report measurement with 20 items
combines these two factors in the Positive and Negative
Affect Schedule (PANAS), comprising two 10-item scales
for PA and NA [64]. The PANAS has been employed in
several studies of long-term adult cancer survivors [45, 46,
54, 55, 66]. In the current study, Cronbach’s alpha coefficient
for negative affect was .91 and that for positive affect was .89.
Other measures
We collected other information that may have affected out-
comes, including age, gender, site of cancer and whether
metastatic or nonmetastatic, date of cancer diagnosis and
duration of cancer condition, and any additional interven-
tions, such as adjuvant cancer treatment, supplements, and
herbal treatments used by participants (see Table 1). We
collected these as part of the screening process prior to the
start of the study, but since this was an exploratory study, we
did not stratify participants based on any of these variables.
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Statistical analyses
The data analyses evaluated: (1) whether the mind–body
programs provided greater benefit for sleep than did the
active control condition and (2) whether the mind–body
programs provided greater additional benefit for other self-
reported measures of coexisting symptoms or psychosocial
indicators than did the active control intervention.
MOS-SS (primary outcome and endpoint) To evaluate these
objectives, we used mixed effects linear models under max-
imum likelihood to estimate the level and change of treat-
ment benefit in the three groups, adjusted for baseline
differences. The primary endpoint of the study based on
the MOS-SS SPI II was the overall benefit from baseline,
i.e., cumulative changes over the four postrandomization
periods comprising week2 (assessed before the beginning of
the second session), week3 (assessed before the beginning of
the third session), post, and follow-up. We controlled for
baseline differences using the prerandomization measures
(baseline) as covariates. In line with the usual analysis of
covariance (ANCOVA) strategy that is strongly recommended
for analyzing clinical trial outcomes by Frison and Pocock
[67], we emphasize that conditioning on baseline covariates
performs statistical matching on the prerandomization scores
and ensures that postrandomization treatment arm compari-
sons are free of baseline differences. A significant F test for
the treatment arms indicates that it is unlikely that the adjusted
population means are exactly equal. While the overall F tests
are informative, since there are three groups in our exploratory
study, they do not provide insight into the magnitudes of
treatment effects. Given this, we constructed customized con-
trasts among the treatment vs. control arms (i.e., MBB vs.
SHE and MM vs. SHE) using the overall postrandomization
averages (comprising week2, week3, post, and follow-up),
adjusted for baseline, to estimate the cumulative benefit of the
three intervention programs individually and relative to one
another.
Other outcomes measures All other primary and secondary
self-report questionnaires were assessed at three time points:
pre, post, and follow-up. In all these analyses, we employed a
mixed effects model ANCOVA with prerandomization
(baseline) score as a covariate and with treatment arm and
Table 1 Demographics, medical history, and baseline self-report data for participants by treatment
SHE MBB MM
Demographics
Age (year) 51.6 (10.7)ab 55.4 (9.6) 50.8 (9.10)
Female 14 13 16
Male 4 6 4
Medical history
Breast cancer 9 8 14
Other cancersc 10d 13d 6
Metastatic cancer 3 3 3
Median years since cancer diagnosis 4 years, 2 months 3 years 8 months 2 years 10 months
Reporting previous diagnosis of insomnia 6 8 8
Reporting previous diagnosis of clinical depression 6 6 7
Medications at baseline
Sleep medications 5 4 5
Antidepressants 9 7 9
Any prescription medications 18 15 19
Any supplements/herbal remedies 16 17 17
Baseline measurese
Sleep problems index II (SPI-II) score (MOS-SS) 54.94 (18.31) 58.01 (14.64) 63.33 (12.70)
Total sleep time (TST, h) 6.33 (1.18) 6.13 (1.08) 6.45 (1.19)
Depression rating (CES-D) 20.83 (12.65) 20.05 (11.56) 21.30 (10.30)
a SD in parentheses; all variables reflect number of subjects, unless indicated
b At baseline for age, the three groups did not differ significantly from one another (p=.308)
c Type of cancer, including ovarian, endometrial, testicular, prostate, lung, melanoma, ependymona, leukemia, kidney, lymphomas (non-Hodgkin’s,
CNS), skin carcinoma, brain, thyroid, and peritoneal
dMore than one cancer site in some individuals
e At prerandomization baseline, the three groups did not significantly differ from one another (SPI, p=.244; TST, p=.685; CES-D, p=.943)
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postintervention assessment time as categorical factors. As
noted above, in line with the usual ANCOVA strategy, condi-
tioning on baseline covariates performs statistical matching on
the prerandomization scores and ensures that postrandomiza-
tion treatment arm comparisons are free of baseline differ-
ences. For each self-report outcome measure, the analysis
estimated overall treatment arm benefit conditional on assess-
ment time. Just as in the primary outcome measure, to gain
insight into the magnitudes of treatment effects, we further
constructed customized contrasts among the treatment vs.
control arms (i.e., MBB vs. SHE and MM vs. SHE) using
the overall postintervention averages (post and follow-up)
adjusted for baseline, to estimate the cumulative benefit of
the three intervention programs individually and relative to
one another.
The mixed effects analysis model generalizes conventional
baseline-adjusted ANCOVA by more flexibly and accurately
incorporating the statistical dependence arising with repeated
observation of the same individuals. We used an objective
criterion, the minimal value of the Bayesian Information Cri-
terion, to determine the most parsimonious fit to alternative
covariance structures of the repeated observations, retaining in
all cases the full treatment arm-by-period factorial for the
fixed effects. Mixed effects analyses invoke an “intent-to-
treat” treatment of missing data by including every observa-
tion of the dependent measure. No observations are discarded,
and no data are imputed. Rather, the algorithm chooses pa-
rameter estimates that generate the highest probability for all
the data observed under the model assumptions.
Results
Attendance
Following the CONSORT recommendations, Fig. 1 depicts
the number of individuals screened, qualified, and enrolled
in the study, as well as retention numbers at post and follow-
up, for each intervention. Of the 57 participants who en-
rolled (18 in SHE, 19 in MBB, 20 in MM), a total of 55
completed the interventions and postintervention question-
naires [17 in SHE (94.4 %), 18 in MBB (94.7 %), and 20 in
MM (100 %)], and 44 completed the 2-month follow-up [13
in SHE (72.2 %), 14 in MBB (73.7 %), and 17 in MM
(85 %)]. Only two participants missed one of the three
classes. All except two participants completed postassess-
ment; however, these two completed the follow-up.
Demographics and baseline characteristics
Table 1 shows demographics and baseline measures, includ-
ing cancer diagnosis and medications used by the 57 study
participants before randomization. Participants were
predominantly non-Hispanic white female and male; two
female and one male participants were Hispanic. Female
was the predominant gender, and female breast cancer sur-
vivors comprised the greatest number of participants (Ta-
ble 1). Baseline characteristics were reasonably well-
balanced among the three groups. Differences in baseline
dependent measures were adjusted directly in the analysis.
Outcome measures
Primary outcomes
MOS-SS Sleep Problems Index 2 Cumulative mean scores,
comprising the four postrandomization data points and ad-
justed for baseline differences, are displayed in Fig. 2. A
dashed horizontal line in Fig. 2 represents the mean baseline
covariate value representing a common reference point
across the three treatment groups. In the ANCOVA, com-
parison of the error covariance structures supported the
compound symmetry (or random intercept) model. The
overall F test for arm was significant (p=.011), indicating
that the average levels differed across treatment arms at
postrandomization. The indicator of effect size in the linear
mixed model (R2b) expressing the effect size of fixed effects
in the linear mixed model [68] was estimated to be .13,
reflecting the magnitude of treatment effects across the three
groups. The estimated mean scores comprising the four
postrandomization data points, adjusted for baseline, and
95 % confidence intervals (CIs) for each of the three treat-
ment groups are presented under “Overall” in Table 2. The
customized contrasts were MBB vs. SHE, p=.0029; MM vs.
SHE, p=.0499, respectively. Table 3 presents effect sizes for
pair-wise comparisons (MBB vs. SHE and MM vs. SHE),
and R2b corresponding to the magnitude of differences
among the treatment groups, which are estimated to be
analogous to Cohen’s d. In addition, all treatment interven-
tions showed benefit in relation to the baseline covariate
(59.19), with mean improvements (i.e., decreases from base-
line) in self-reported sleep scores of 22.29 for MBB, 18.70
for MM, and 12.11 for SHE (all p<0.001).
The adjusted means and 95 % CIs of the three groups at
weeks 2 and 3 are presented in Table 2. Further inspection of
these values indicated that during the active treatment peri-
od, there was no differential benefit immediately across the
three groups. The adjusted means and 95 % CIs of the three
groups at post and at follow-up are presented in Table 2. The
customized contrasts at post were: MBB vs. SHE, p=.001
and MM vs. SHE, p=.065, respectively. The customized
contrasts at follow-up were MBB vs. SHE, p=.018, and
MM vs. SHE, p=.040, respectively. Figure 3 presents all
adjusted means from the three groups over time.
For the other MOS-SS subscales, in accordance with
greater improvements as indexed by SPI-II in sleep in the
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MBB and MM treatment groups, some subscales (adequacy,
disturbance, and somnolence) revealed differences across
the three interventions (see Table 4, statistics not shown).
Table 4 shows unadjusted means and standard deviations of
SPI-II and other subscales from the three groups at baseline,
post and follow-up. Table 5 presents a pooled within-group
covariance matrix with variances in diagonal and correla-
tions off-diagonal for SPI-II. Table 6 presents unadjusted
means and standard deviations of SPI-II from the three
groups at six time points. All these data were used in the
statistical analyses reported above. Data from Tables 5 and 6
should facilitate a systematic review and meta-analysis of
MBIs in the future.
The proportions of cancer survivors whose MOS-SS
scores fell and remained below the cutoff point for signifi-
cant sleep disturbance (MOS-SS SPI-II score of 35 as used
in the eligibility assessment) after completion of the inter-
vention programs were as follows: At post, the proportions
were 29.4 % below the cutoff for SHE, 66.7 % below the
cutoff for MBB, and 45.0 % below the cutoff for MM. At
follow-up, the proportions were 46.2 % below the cutoff for
SHE, 57.1 % below the cutoff for MBB, and 52.9 % below
the cutoff for MM.
In summary, all treatments provided apparent benefit
from preintervention baselines. Figure 3 graphically illus-
trates that SHE was effective while the intervention sessions
were ongoing, but MM and MBB were effective longer after
the completion of the study program. It appears that MBB
may have maintained a constant relative superiority of 3–4
points over MM throughout the duration of the study.
Functional Assessment of Cancer Therapy—General Total
FACT-G scores increased by 3–7 points in the three inter-
ventions (Table 7). Both active interventions showed
Fig. 1 Study flow, described in
accordance with the CONSORT
Guidelines
Fig. 2 Primary outcome indicator, the adjusted means of MOS-SS
Sleep Problems Index II (SPI-II), averaged over all time points in the
three groups, with 95 % confidence interval (CI). Here, “adjusted”
means “adjusted for baseline scores,” allowing the outcome indicators
to be directly compared with one another. Both MM and MBB were
found to be lower than SHE (p=.0499 and p=.0029 respectively). Note
that the CIs depicted here are not those CIs actually used in the linear
mixed model analysis. A dashed horizontal line in represents the mean
baseline covariate value, representing a common baseline reference
across the three groups
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benefit, with mean improvements of 7.47 (p=.002) for
MBB and 6.0 (p=.010) for MM, while the SHE control
group produced an improvement of 3.94 (p=.116), from
the baseline covariate value (72.40). However, ANCOVA
revealed no significant difference across the groups
(p=.625). Comparisons of mean scores for each FACT-G
subscale indicated that there is no difference among the
groups (data not shown). Nonetheless, the observed overall
improvements in the three groups are comparable to the
minimally important difference, the magnitude of 3–7 points
change reported for the FACT-G overall score [69]. This
suggests that all interventions positively impacted QOL as
measured by FACT-G.
Perceived Stress Scale The adjusted means of PSS 10 de-
creased in MBB (4.77), MM (3.01), and SHE (2.71) from
the baseline covariate value of 18.60. Table 7 presents
unadjusted means of PSS across the three groups. The
mixed effects ANCOVA indicated that the three groups
did not differ from one another (p=.279). The magnitude
of change observed in the MBB group seems comparable to
that (4.7 from pre to post) reported in one recent study of
MBSR for cancer survivors [70] or those (5.7 from pre to
post or 3.8 improvement relative to the wait-list control)
reported in another recent study of MBSR for cancer
patients [52].
Secondary outcomes
Center for Epidemiological Studies-Depression rating scale—
total score All treatment interventions showed apparent ben-
efit from baseline levels, with mean improvements of 8.58 (p
=.001) for MBB, 4.36 (p=.008) for MM, and 3.25 (p=.064)
for SHE, in overall postintervention level. The magnitudes of
these improvements are larger or comparable to what was
reported (4.7 improvement from pre to post) in a recent
Table 2 Adjusted means (and
95 % CIs) of MOS-SS SPI-II
scores and other secondary
measures for comparisons
among SHE, MBB, and MM
aOverall=average of four scores
at four different time points,
which was defined as the
primary outcome measure for
the primary analysis
Scale SHE MBB MM
MOS-sleep scale SPI-II
Overalla 47.08 (42.33–51.88) 36.89 (32.30–41.48) 40.49 (36.02–44.96)
Week2 49.96 (44.55–55.37) 44.78 (39.56–50.01) 46.65 (41.52–51.79)
Week3 44.82 (38.93–50.71) 39.89 (34.09–45.68) 41.81 (36.22–47.40)
Post 50.04 (43.27–56.80) 32.94 (26.37–39.50) 41.29 (34.97–47.61)
Follow-up 43.52 (35.53–51.52) 29.97 (22.27–37.68) 32.20 (25.05–39.35)
CES-D total score 16.97 (13.59–20.35) 12.03 (8.75–15.31) 16.32 (13.20–19.44)
FF-MQ total score 129.30 (123.31–135.30) 139.51 (133.68–145.33) 133.27 (127.68–138.87)
Subscales
Acting with awareness 25.55 (23.75–27.34) 27.82 (26.07–29.56) 24.67 (22.99–26.36)
Observing 27.86 (26.47–29.26) 29.92 (28.57–31.27) 29.47 (28.18–30.77)
SCS total score 82.09 (77.62–86.56) 89.15 (84.81–93.48) 86.44 (82.28–90.59)
WBI total score 14.16 (12.74–15.58) 16.54 (15.16–17.92) 15.24 (13.92–16.57)
Table 3 Cohen’s effect sizes for pair-wise comparisons and R2b for 3-
group comparison for primary and secondary outcome measures
Cohen’s effect size (d) estimates Overall
effect size
MBB vs. SHE MM vs. SHE R2b
MOS-SS SPI-II 1.06 0.70 .13
CES-D .44 .06 .09
FF-MQ .52 .21 .10
SCS .32 .20 .09
WBI .52 .28 .10
Fig. 3 Estimated mean scores of SPI-II adjusted for baseline scores
from pre, for SHE (dotted line), MBB (solid line), and MM (dashed
line), as a function of assessment times (week 2, week 3, post, and
follow-up). Here, “adjusted” means “adjusted for baseline scores,”
allowing them to be directly compared with one another. Therapeutic
benefits in MM and MBB continued to improve over time, while that
in SHE leveled off after the completion of the study sessions. A dashed
horizontal line in represents the mean baseline covariate value, repre-
senting a common baseline reference across the three groups
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feasibility study of an MBSR program for early stage breast
cancer survivors [70]. Mixed effects ANCOVA of CES-D
yielded p=.078 and R2b =.088, overall. The adjusted means
and 95% CIs of the three groups are presented in Table 2. The
customized contrasts were MBB vs. SHE, p=.040, and MM
vs. SHE, p=.776, respectively. Figure 4a shows these adjusted
means graphically (see Table 7 for unadjusted means and
standard deviations of CES-D scores).
This suggests that MBB was more effective than SHE in
reducing self-reported depression symptoms (see Table 3 for
estimated effect sizes involving the CES-D). It is important
to recognize that all three study interventions were focused
on specifically improving sleep. Nonetheless, the data
suggest that MBB reduced self-reported depression symp-
toms even though the MBB program did not explicitly
address depression.
Impact of event scale IES measures, as indicated by adjust-
ed mean scores, decreased in MBB (6.43), MM (2.13), and
SHE (2.9), respectively. Table 7 presents unadjusted means
of IES across the three groups. The ANCOVA indicated that
the groups did not differ from one another (p=.543). These
observed reductions are comparable to those reported in an-
other recent study ofMBSR for cancer patients (approximately
2–3 point reductions in MBSR group and approximately 1
point reduction in the wait-list control)[52].
Table 4 Unadjusted means (and
SDs) of MOS-SS subscale
scores by treatment
aFor MOS-SS Sub-scales,
baseline score reflects the value




Sleep disturbance Baselinea 59.44 (25.90) 64.47 (21.50) 69.25 (17.90)
Post 46.84 (23.64) 32.57 (20.32) 46.69 (23.81)
Follow-up 39.13 (16.85) 31.79 (24.09) 37.50 (24.59)
Snoring Baseline 35.29 (32.04) 34.12 (26.23) 34.00 (38.44)
Post 30.00 (37.24) 28.24 (29.21) 33.68 (42.19)
Follow-up 33.85 (38.63) 28.57 (31.10) 28.24 (33.95)
Awaken with shortness
of breath/headache
Baseline 28.89 (29.28) 17.89 (20.97) 30.00 (34.64)
Post 16.47 (29.36) 12.22 (24.87) 13.00 (20.80)
Follow-up 23.08 (30.38) 5.71 (12.22) 7.06 (14.04)
Somnolence Baseline 41.11 (24.44) 42.46 (21.68) 42.33 (13.90)
Post 37.25 (23.69) 25.56 (19.57) 26.00 (17.69)
Follow-up 30.77 (28.74) 24.29 (18.78) 26.27 (12.58)
Sleep adequacy Baseline 35.56 (21.75) 25.26 (19.82) 21.00 (17.14)
Post 34.71 (24.52) 52.78 (21.64) 36.00 (21.86)
Follow-up 43.85 (27.25) 51.43 (22.14) 48.24 (24.04)
Sleep problems index I Baseline 52.41 (18.11) 56.84 (13.03) 62.33 (13.12)
Post 45.29 (17.84) 32.04 (14.51) 43.17 (15.76)
Follow-up 40.77 (18.72) 31.19 (15.45) 35.10 (18.60)
Sleep problems index II Baseline 54.94 (18.31) 58.01 (14.64) 63.33 (12.70)
Post 47.22 (16.21) 32.13 (14.81) 43.64 (17.44)
Follow-up 40.81 (18.64) 31.59 (16.95) 36.01 (17.52)
Baseline 6.33 (1.18) 6.13 (1.08) 6.45 (1.19)
Sleep duration (hr.) Post 6.41 (1.57) 6.97 (1.09) 7.00 (1.21)
Follow-up 6.92 (1.55) 6.79 (1.05) 7.09 (1.75)
Table 5 MOS-SS Sleep Prob-
lems Index-II (SPI-II) subscale
indicating a pooled within-group
covariance matrix with variances
in diagonal and correlations
off-diagonal
Pre 1 Pre 2 Week2 Week3 Post Follow-up
Pre1 (221.50) .85 .64 .55 .39 .44
Pre2 (194.78) .64 .51 .34 .39
Week2 (207.22) .62 .44 .45
Week3 (219.33) .72 .55
Post (245.88) .65
Follow-up (285.45)
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Five-facet Mindfulness Questionnaire As shown in Fig. 4b,
mindfulness in the MM and MBB groups seemed to in-
crease at postrandomization. ANCOVA on total FF-MQ
scores yielded p=.056 and R2b =.101, overall. The adjusted
mean total mindfulness scores (comprising all mindful-
ness subscales) and 95 % CIs of the three groups are
presented in Table 2. The customized contrasts were
MBB vs. SHE, p=.018, and MM vs. SHE, p=.335,
respectively. Figure 4b presents these adjusted means
graphically. Table 7 presents unadjusted means and stan-
dard deviations of FF-MQ. This suggests that MBB was
more effective than SHE in increasing self-reported
mindfulness (see Table 3 for estimated effect sizes in-
volving the FF-MQ).
Since it is advantageous to assess separately the effects of
the interventions on subscales of FF-MQ, we examined each
subscale independently. For the FF-MQ subscale “acting
with awareness,” the ANCOVA yielded p=.036, overall.
The adjusted mean scores and 95 % CIs of the three groups
are presented in Table 2. The customized contrasts were
MBB vs. SHE, p=.075, and MM vs. SHE, p=.480, respec-
tively. For the FF-MQ subscale “observing,” the ANCOVA
yielded p=.093, overall. The adjusted mean scores and 95 %
CIs of the three groups are presented in Table 2. The
customized contrast were MBB vs. SHE, p=.038, and
MM vs. SHE, p=.096, respectively. None of the other three
FF-MQ subscales were able to detect reliable differences
among the three intervention groups.
Table 6 Unadjusted means (and SDs) of MOS-SS SPI-II by treatment
at different time points
SHE MBB MM
Pre1 54.94 (18.31) 58.01 (14.64) 63.33 (12.70)
Pre2 54.57 (17.04) 57.08 (14.94) 61.42 (10.63)
Week2 47.61 (14.32) 44.15 (15.34) 49.00 (14.67)
Week3 42.47 (12.54) 39.23 (18.00) 44.16 (14.88)
Post 47.22 (16.21) 32.13 (14.81) 43.64 (17.44)
Follow-up 40.81 (18.64) 31.59 (16.95) 36.01 (17.52)
Table 7 Unadjusted means (and




FACT-G Baseline 71.59 (20.76) 73.12 (15.52) 70.92 (15.16)
Post 76.50 (15.88) 78.54 (17.65) 74.88 (16.14)
Follow-up 79.54 (14.81) 81.20 (18.10) 78.17 (16.45)
PSS total score Baseline 17.56 (7.49) 18.53 (6.10) 20.20 (7.35)
Post 15.41 (7.83) 14.82 (4.29) 16.90 (4.85)
Follow-up 15.08 (6.33) 11.85 (5.03) 15.29 (5.63)
CES-D total score Baseline 20.83 (12.65) 20.05 (11.56) 21.30 (10.30)
Post 16.65 (9.85) 12.67 (8.85) 18.25 (10.86)
Follow-up 17.15 (12.78) 10.57 (10.11) 15.18 (10.17)
IES total score Baseline 33.20 (16.18) 37.06 (14.57) 33.89 (16.15)
Post 27.12 (15.78) 32.11 (16.95) 34.16 (15.23)
Follow-up 32.23 (17.59) 25.59 (14.33) 31.75 (13.45)
FF-MQ total score Baseline 125.06 (22.32) 128.32 (15.65) 124.45 (21.69)
Post 125.71 (24.44) 139.61 (12.66) 129.50 (20.58)
Follow-up 133.54 (24.64) 141.00 (11.99) 135.18 (20.43)
SCS total score Baseline 86.28 (26.48) 80.11 (20.14) 80.30 (21.89)
Post 82.35 (23.66) 84.33 (17.59) 82.70 (19.33)
Follow-up 88.77 (25.35) 89.86 (22.37) 87.88 (19.82)
WBI total score (well-being) Baseline 11.11 (4.99) 11.53 (4.54) 11.25 (4.54)
Post 13.41 (4.77) 16.39 (4.16) 14.35 (3.65)
Follow-up 15.92 (4.25) 17.00 (3.14) 15.76 (4.34)
PANAS-negative affect Baseline 21.22 (9.96) 20.53 (6.78) 20.85 (7.39)
Post 17.47 (8.52) 16.78 (6.28) 17.35 (6.12)
Follow-up 19.23 (9.45) 15.57 (6.85) 16.88 (6.21)
PANAS -positive affect Baseline 28.44 (7.76) 27.84 (6.70) 29.00 (8.02)
Post 29.24 (7.80) 31.11 (7.36) 30.75 (6.55)
Follow-up 31.77 (6.47) 34.14 (7.20) 33.76 (6.30)
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It may be important to note that the MBB intervention did
not include any formal mindfulness meditation exercises,
while the MM intervention included several types of mindful-
ness meditation techniques (sitting, walking, and body scan).
Nonetheless, MBB proved to be the intervention that in-
creased the overall level of mindfulness in comparison with
SHE.
Self-Compassion Scale The MBB and MM treatments
showed apparent benefit, withmean improvements from base-
line levels of 7.25 (p=.002) for MBB and 4.38 (p=.046) for
MM, but SHE showed virtually no change (.177, p=.939), in
overall postintervention level. ANCOVA of total Self-
Compassion scores yielded p=.084 and R2b =.089, overall.
The adjusted means and 95 % CIs of the three groups are
presented in Table 2. The customized contrasts were MBB vs.
SHE, p=028, and MM vs. SHE, p=160, respectively.
Figure 4c presents these adjusted means graphically. Table 7
presents unadjusted means and standard deviations of this
measure. This suggests that MBB was more effective than
SHE in increasing self-reported measures of self-compassion
(see Table 3 for estimated effect sizes involving the SCS).
WHO Well-Being Index All treatment interventions
showed benefit, with mean improvements from baseline
levels of 4.96 (p=.001) for MBB, 3.77 (p=.001) for
MM, and 2.70 (p=.001) for SHE, in overall postintervention
levels. ANCOVA of total Well-Being Index (WBI) scores
yielded p=.062 and R2b =.095, overall. The adjusted mean
scores and 95 % CIs of the three groups are presented in
Table 2. The customized contrasts were MBB vs. SHE, p=
019, and MM vs. SHE, p=267, respectively. Figure 4d
presents these adjusted means graphically. Table 7 presents
unadjusted means and standard deviations of this measure.
This suggests that MBB was more effective than SHE in
increasing self-reported measures of well-being (see Table 3
for estimated effect sizes involving WBI).
Positive and Negative Affect Schedule Negative affect de-
creased in MBB (4.57), MM (3.79), and SHE (2.85) as
c d
a b
Fig. 4 Effects of the three sleep interventions on: a) depression symp-
toms (CES-D), b) mindfulness (FF-MQ), c) self-compassion (SCS),
and d) well-being (WBI). Estimated means, adjusted for baseline
scores from Pre, for each scale are presented for SHE, MBB, and
MM, with 95 % Confidence Interval (CI). Here, “adjusted” means
“adjusted for baseline scores,” allowing them to be directly compared
with one another. Note that the CIs depicted in Figure 4a, 4b, 4c, and
4d are not those CIs actually used in linear mixed model analysis. In all
scales, MBB was different from SHE at post-intervention, indicating
that MBB led to a reduced level of self-reported depression symptoms
(4a) and enhanced levels of mindfulness, self-compassion, and well-
being (4b, 4c, 4d). A dashed horizontal line in each Figure represents
the mean baseline covariate value of each scale, representing a com-
mon baseline reference across the three groups
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indicated by adjusted mean scores. For positive affect, ad-
justed mean scores increased in MBB (3.46), MM (2.83),
and SHE (1.0). However, the ANCOVA indicated that the
groups did not statistically differ from one another for
negative (p=.612) and positive affect (p=.278) (see Table 7
for unadjusted means and standard deviations of PANAS
scores).
Discussion
The present study provided preliminary evidence that cancer
survivors can benefit from brief sleep-focused mind–body
programs to improve their sleep. As hypothesized, MBB
and MM performed better than SHE in decreasing self-
reported sleep disturbance. Although both MBB and MM
helped cancer survivors improve sleep, benefits seemed to
emerge at different times. While MBB provided more benefit
at program completion (at post), at 2-month follow-up, MM
was found be equally as effective asMBB. This may be due to
differential learning curves required for the two techniques.
Data from the present study suggest that both MBB and MM
can serve as effective interventions for sleep management in
posttreatment cancer survivors.
In addition, MBB was found to have further benefits in
comparison with the active control (SHE): (1) it decreased
self-reported symptoms of depression, and (2) it increased
overall levels of mindfulness, self-compassion, and well-
being. These changes came about even though MBB was
not specifically designed to explicitly address issues
concerning these domains. The fact that MBB was effective
in attenuating depressive symptoms was consistent with the
similar pattern observed in our earlier study of MBB, al-
though in the earlier study it did not reach statistical signif-
icance [33]. MM did not produce any reliable change in
these secondary outcomes. These results provide prelimi-
nary support for the intriguing possibility that sleep-focused
MBB can help cancer survivors not only with sleep distur-
bance but also with other comorbid symptoms such as
depression.
In contrast, there were no reliable improvements in
FACT-G, PSS, IES, and PANAS with either MBB or MM.
As noted above, both MBB and MM produced improve-
ments in FACT-G that are comparable to the magnitude of
clinically meaningful changes reported in the literature [69],
and this suggests that the mean improvements observed in
the MBB and MM groups are in fact clinically meaningful
by conventional standards. Similarly, the magnitudes of
changes measured by IES and PSS in the MBB and MM
groups are comparable to those reported in two recent stud-
ies of MBSR for cancer patients or survivors [52, 70].
Furthermore, it may be the case that these indicators (e.g.,
IES, PSS, PANAS) are more resistant to short-term changes.
Our interventions were designed to exclusively deal with
cancer survivors’ problems concerning sleep. Given the
possibility that improved sleep can influence other coexist-
ing health conditions, we hypothesized that such sleep-
focused interventions might also improve comorbid symp-
toms. Our objective was to explore the potential value of
MBB and MM in improving self-reported sleep and comor-
bid symptoms in a cross-section of posttreatment cancer
survivors, regardless of the type of sleep problems experi-
enced or the origins of their sleep problems. Overall, the
data are consistent with the hypothesis that MBB and MM
can improve self-reported sleep quality in cancer survivors.
However, we cannot yet claim that MBB or MM effectively
treated specific sleep disorder conditions (such as insomnia)
as assessed by clinical evaluation. Further research would
need to explore potential benefits for specific sleep disorders
such as primary, secondary, or comorbid insomnia, sleep
apnea, restless leg syndrome, or sleep-disordered breathing.
The present study provided strong support for the idea
that three weekly sessions of MBB or MM can yield mean-
ingful sleep improvement. Our data are consistent with
previous research using other interventions to improve
sleep. Cognitive behavioral therapy also has been shown
to be effective over a short-term period (1–4 sessions) [71,
72]. However, MBSR-type interventions may require longer
durations (i.e., 6 sessions or longer) to exert their effects (for
more on this issue see Carmody [73]), given that meditation
practice might require a longer time span in order for it to
generate sustained benefits.
The effectiveness of mindfulness practices in facilitating
health and well-being, including sleep, has been reported in
numerous studies utilizing several interventions [7, 17, 32,
74–78]. We postulated that increased mindfulness might have
contributed to improvements in sleep and reductions in self-
reported symptoms such as depression. Changes in mindful-
ness in the MBB group of this study are notable, especially
given (1) the brief nature of the intervention (three sessions,
once per week) and (2) the fact that, unlike other mindfulness-
based interventions, MBB does not include formal meditation
practice. However, MBB included everyday awareness prac-
tices, which are analogous to informal practice of mindful-
ness. This suggests the possibility that cancer survivors in the
MBB group were able to engage in awareness practices with-
out necessarily first going through formal mindfulness practi-
ces, in the form of sitting and walking meditation. The overall
level of mindfulness increased in theMMgroup, but it was not
statistically different from that in the control SHE group,
despite the fact that MM improved sleep considerably.
Our exploratory study included participants in remission
from a range of cancer types. Since this study assessed efficacy
ofMBB andMM as novel sleepmanagement interventions, we
did not exclude any specific sleep problems. Although it would
be desirable to conduct an additional analysis using cancer type
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or specific sleep disorder as a covariate, the smaller sample size
in the present study made it unfeasible to carry out this. Future
studies with a bigger sample should investigate this issue.
Nonetheless, given positive improvements from the two
mind–body intervention groups, these inclusive selection crite-
ria may actually contribute to the enhanced generalizability of
our findings to the larger cancer survivor population. These
results have important implications for selectively targeting
sleep in cancer survivors, with potential additional benefits for
comorbid symptoms such as depression.
In this study, MM did not produce beneficial changes in
other indicators of psychosocial functioning. This may re-
late to the question of what “dose” of a mind–body inter-
vention is required to produce observable benefits. MBSR
has usually been implemented as an 8-week program since
its inception; more recently, sleep-focused MBSR has been
implemented as a 6-week program. In our study, MM was
given in just three sessions over 3 weeks in accordance with
the duration of the MBB program. This may have limited
the efficacy of MM, and it would be reasonable to suspect
that more sessions given over a longer time period might
have made MM more effective in increasing MM’s impact
on these other psychosocial indicators.
The present exploratory study produced some encouraging
findings, but we are keenly aware of limitations that should be
addressed in future clinical trials of MBB and MM. Limita-
tions of our study include the following: the investigative
method used to verify the mental health and remission status
of study participants; no clinical (i.e., medical) evaluation of
study participants with respect to the nature of sleep distur-
bances and other comorbid conditions (cancer survivors par-
ticipating in the study, however, had been seeing their health
care providers for any posttreatment problems); exclusive
reliance on self-report measures; no explicit assessment of
intervention fidelity; the lack of an explicit measure of home
practice in the MM and MBB groups; and no measures of
daily changes in sleep patterns based on sleep diary data.
Recently, Garland and her colleagues [79] proposed a
randomized controlled noninferiority trial in which MBSR
will be compared with Cognitive Behavior Therapy for
Insomnia (CBT-I, a known efficacious treatment). This de-
sign can efficiently compare these two treatments directly
and determine whether MBSR performs to the same stan-
dard as CBT-I for the treatment of insomnia with additional
benefits of reducing cancer-related comorbid symptoms.
Employing this type of study design may prove to be useful
in further investigating MBB together with other proven
treatments such as CBT-I.
The present exploratory study suggest that MBB and
MM can serve as effective mind–body interventions for
posttreatment care of cancer survivors with self-reported
sleep disturbance. Furthermore, because MBB in particular
is easy to learn and cumulative benefits are obtained within
only a few sessions, MBB may be an ideal vehicle for
managing multiple coexisting symptoms in cancer survi-
vors. However, more research is clearly needed to determine
if MBB may specifically serve as a front-loaded program for
addressing sleep problems and comorbid psychological con-
ditions like depression in posttreatment cancer survivors.
Additionally, future studies might investigate the degree to
which mind–body interventions may enable cancer survivors
to reduce use of sleep medication. MBB in particular, and
MBIs in general, can empower cancer survivors to manage
complex symptoms, enhance quality of life, and regain more
optimal functioning.
Acknowledgments The study reported was supported by National
Institutes of Health (NIH) Award R21 AT002209 to the first author
from the National Center for Complementary and Alternative Medicine
(NCCAM). The content is solely the responsibility of the authors and
does not necessarily represent the official views of the NCCAM or
NIH. NIH and NCCAM had no role in the conduct of the study,
collection, management, analysis, and interpretation of the data and
preparation, review or approval of the manuscript. The authors would
like to thank Richard Landward, LCSW, for developing and refining a
brief Mind–Body Bridging program based on our earlier study that we
collaboratively conducted. The authors would like to thank Dr. Saundra
Buys for initial consultation about the present study. The authors would
like to thank the clinicians who served as the instructors for the interven-
tion programs investigated in the study: Richard Landward, LCSW
(Mind–Body Bridging), PeggyHunter, LCSW (MindfulnessMeditation),
and Katie Porter, LCSW (sleep hygiene education). Lastly, the authors
would like to express deep appreciation for the effort and time devoted by
the cancer survivors who participated in the study.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR.
Neuroendocrine-immune mechanisms of behavioral comorbidities
in patients with cancer. J Clin Oncol. 2008;26(6):971–82.
2. Ancoli-Israel S. Recognition and treatment of sleep disturbances in
cancer. J Clin Oncol. 2009;27(35):5864–6.
3. Bower JE. Behavioral symptoms in patients with breast cancer and
survivors. J Clin Oncol. 2008;26(5):768–77.
4. Savard J, Morin CM. Insomnia in the context of cancer: a review
of a neglected problem. J Clin Oncol. 2001;19(3):895–908.
5. Savard J, Simard S, Blanchet J, Ivers H, Morin CM. Prevalence,
clinical characteristics, and risk factors for insomnia in the context
of breast cancer. Sleep. 2001;24(5):583–90.
6. Degner LF, Sloan JA. Symptom distress in newly diagnosed am-
bulatory cancer patients and as a predictor of survival in lung
cancer. J Pain Symp Manag. 1995;10(6):423–31.
7. Shapiro SL, Bootzin RR, Figueredo AJ, Lopez AM, Schwartz GE.
The efficacy of mindfulness-based stress reduction in the treatment
of sleep disturbance in women with breast cancer: an exploratory
study. J Psychosom Res. 2003;54(1):85–91.
J Cancer Surviv (2013) 7:165–182 179
8. Kvale EA, Shuster JL. Sleep disturbance in supportive care of
cancer: a review. J Palliat Med. 2006;9(2):437–50. doi:10.1089/
jpm.2006.9.437.
9. Astin JA, Shapiro SL, Eisenberg DM, Forys KL. Mind–body
medicine: state of the science, implications for practice. J Am
Board Fam Pract. 2003;16(2):131–47.
10. Begley S. Train your mind, change your brain: how a new science
reveals our extraordinary potential to transform ourselves. New
York: Ballantine; 2007.
11. Shapiro SL, Carlson LE, Astin JA, Freedman B. Mechanisms of
mindfulness. J Clin Psychol. 2006;62(3):373–86. doi:10.1002/
jclp.20237.
12. Kabat-Zinn J. An outpatient program in behavioral medicine for
chronic pain patients based on the practice of mindfulness medi-
tation: theoretical considerations and preliminary results. Gen
Hosp Psychiatr. 1982;4(1):33–47.
13. Kabat-Zinn J, Lipworth L, Burney R. The clinical use of mindful-
ness meditation for the self-regulation of chronic pain. J Behav
Med. 1985;8(2):163–90.
14. Teasdale JD, Moore RG, Hayhurst H, Pope M, Williams S, Segal
ZV. Metacognitive awareness and prevention of relapse in depres-
sion: empirical evidence. J Consult Clin Psychol. 2002;70(2):275–
87.
15. Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM,
Lau MA. Prevention of relapse/recurrence in major depression by
mindfulness-based cognitive therapy. J Consult Clin Psychol.
2000;68(4):615–23.
16. Block SH, Block CB. Come to your senses: demystifying the
mind–body connection. 2nd ed. New York: Atria Books–Beyond
Words; 2007.
17. Shapiro SL, Carlson LE. The art and science of mindfulness:
integrating mindfulness into psychology and the helping profes-
sions. American Psychological Association, D.C.; 2009.
18. Carlson LE, Garland SN. Impact of mindfulness-based stress re-
duction (MBSR) on sleep, mood, stress and fatigue symptoms in
cancer outpatients. Int J Behav Med. 2005;12(4):278–85.
19. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based
stress reduction in relation to quality of life, mood, symptoms of
stress, and immune parameters in breast and prostate cancer out-
patients. Psychosom Med. 2003;65(4):571–81.
20. Carlson LE, Speca M, Patel KD, Goodey E. Mindfulness-based
stress reduction in relation to quality of life, mood, symptoms of
stress and levels of cortisol, dehydroepiandrosterone sulfate
(DHEAS) and melatonin in breast and prostate cancer outpatients.
Psychoneuroendocrinology. 2004;29(4):448–74.
21. Lengacher CA, Johnson-Mallard V, Post-White J, Moscoso MS,
Jacobsen PB, Klein TW, et al. Randomized controlled trial of
mindfulness-based stress reduction (MBSR) for survivors of breast
cancer. Psycho Oncol. 2009;18(12):1261–72.
22. Lengacher CA, Reich RR, Post-White J, Moscoso M, Shelton
MM, Barta M, et al. Mindfulness based stress reduction in post-
treatment breast cancer patients: an examination of symptoms and
symptom clusters. J Behav Med. 2012;35(1):86–94. doi:10.1007/
s10865-011-9346-4.
23. Henderson VP, Clemow L, Massion AO, Hurley TG, Druker S,
Hebert JR. The effects of mindfulness-based stress reduction on
psychosocial outcomes and quality of life in early-stage breast
cancer patients: a randomized trial. Breast Canc Res Treat.
2012;131(1):99–109. doi:10.1007/s10549-011-1738-1.
24. Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholls PG, Harrington
JE, Thomas PW. Effectiveness of mindfulness-based stress reduc-
tion in mood, breast- and endocrine-related quality of life, and
well-being in stage 0 to III breast cancer: a randomized,
controlled trial. J Clin Oncol. 2012;30(12):1335–42. doi:10.1200/
JCO.2010.34.0331.
25. Lerman R, Jarski R, Rea H, Rea H, Gellish R, Vicini F, Vicini F.
Improving symptoms and quality of life of female cancer survi-
vors: a randomized controlled study. Ann Surg Oncol. 2012;19
(2):373–8. doi:10.1245/s10434-011-2051-2.
26. Greene PB, Philip EJ, Poppito SR, Schnur JB. Mindfulness and
psychosocial care in cancer: historical context and review of cur-
rent and potential applications. Palliat Support Care. 2012.
doi:10.1017/S1478951511001015.
27. Piet J, Wurtzen H, Zachariae R. The effect of mindfulness-based
therapy on symptoms of anxiety and depression in adult cancer
patients and survivors: a systematic review and meta-analysis. J
Consult Clin Psychol. 2012. doi:10.1037/a0028329.
28. Stan DL, Collins NM, Olsen MM, Croghan I, Pruthi S. The
evolution of mindfulness-based physical interventions in
breast cancer survivors. Evid Base Compl Alternative Med.
2012;2012:758641. doi:10.1155/2012/758641.
29. Zainal NZ, Booth S, Huppert FA. The efficacy of mindfulness-
based stress reduction on mental health of breast cancer patients: a
meta-analysis. Psycho Oncol. 2012. doi:10.1002/pon.3171.
30. Winbush NY, Gross CR, Kreitzer MJ. The effects of mindfulness-
based stress reduction on sleep disturbance: a systematic review.
Explore (NY). 2007;3(6):585–91.
31. Gross CR, Kreitzer MJ, Reilly-Spong M, Wall M, Winbush NY,
Patterson R, et al. Mindfulness-based stress reduction versus
pharmacotherapy for chronic primary insomnia: a randomized
controlled clinical trial. Explore (NY). 2011;7(2):76–87. doi:10.1016/
j.explore.2010.12.003.
32. Britton WB, Haynes PL, Fridel KW, Bootzin RR. Polysomno-
graphic and subjective profiles of sleep continuity before and
after mindfulness-based cognitive therapy in partially remitted
depression. Psychosom Med. 2010;72:539–48. doi:10.1097/
PSY.0b013e3181dc1bad.
33. Nakamura Y, Lipschitz DL, Landward R, Kuhn R, West G. Two
sessions of sleep-focused mind–body bridging improve self-
reported symptoms of sleep and PTSD in veterans: A pilot ran-
domized controlled trial. J Psychosom Res. 2011;70(4):335–45.
doi:10.1016/j.jpsychores.2010.09.007.
34. Chiesa A, Serretti A. A systematic review of neurobiological and
clinical features of mindfulness meditations. Psychol Med.
2010;40(8):1239–52. doi:10.1017/S0033291709991747.
35. Tollefson DR, Webb K, Shumway D, Block SH, Nakamura Y. A
mind–body approach to domestic violence perpetrator treatment:
program overview and preliminary outcomes. J Aggression Maltreat
Trauma. 2009;18:17–45.
36. Rounsaville BJ, Carroll KM, Onken LS. A stage model of behav-
ioral therapies research: getting started and moving on from stage
I. Clin Psychol Sci Pract. 2001;8(2):133–42.
37. Bloom JR, Petersen DM, Kang SH. Multi-dimensional quality of
life among long-term (5+ years) adult cancer survivors. Psycho
Oncol. 2007;16(8):691–706. doi:10.1002/pon.1208.
38. Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland
CS. Symptom burden in cancer survivors 1 year after diagno-
sis: a report from the American Cancer Society’s Studies of
Cancer Survivors. Cancer. 2011;117(12):2779–90. doi:10.1002/
cncr.26146.
39. Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric prop-
erties of the Medical Outcomes Study Sleep measure. Sleep Med.
2005;6(1):41–4. doi:10.1016/j.sleep.2004.07.006.
40. Kabat-Zinn J. Full catastrophe living: Using the wisdom of your
body and mind to face stress, pain, and illness. New York: Delta;
1991.
180 J Cancer Surviv (2013) 7:165–182
41. Grossman P, Niemann L, Schmidt S, Walach H. Mindfulness-
based stress reduction and health benefits. A meta-analysis. J
Psychosom Res. 2004;57(1):35–43. doi:10.1016/S0022-3999
(03)00573-7.
42. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE,
Belin TR. Fatigue in breast cancer survivors: occurrence, correlates,
and impact on quality of life. J Clin Oncol. 2000;18(4):743–53.
43. Thomas KS, Bower J, Hoyt MA, Sepah S. Disrupted sleep in
breast and prostate cancer patients undergoing radiation therapy:
the role of coping processes. Psycho Oncol. 2010;19(7):767–76.
doi:10.1002/pon.1639.
44. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al.
The functional assessment of cancer therapy scale: development
and validation of the general measure. J Clin Oncol. 1993;11
(3):570–9.
45. Helgeson VS, Tomich PL. Surviving cancer: a comparison of 5-
year disease-free breast cancer survivors with healthy women.
Psycho Oncol. 2005;14(4):307–17. doi:10.1002/pon.848.
46. Tomich PL, Helgeson VS. Five years later: a cross-sectional com-
parison of breast cancer survivors with healthy women. Psycho
Oncol. 2002;11(2):154–69. doi:10.1002/pon.570.
47. Holzner B, Kemmler G, Kopp M, Moschen R, Schweigkofler H,
Dunser M, et al. Quality of life in breast cancer patients–not
enough attention for long-term survivors? Psychosomatics.
2001;42(2):117–23.
48. Wenzel LB, Donnelly JP, Fowler JM, Habbal R, Taylor TH, Aziz
N, et al. Resilience, reflection, and residual stress in ovarian cancer
survivorship: a gynecologic oncology group study. Psycho Oncol.
2002;11(2):142–53. doi:10.1002/pon.567.
49. Bradley S, Rose S, Lutgendorf S, Costanzo E, Anderson B. Qual-
ity of life and mental health in cervical and endometrial cancer
survivors. Gynecol Oncol. 2006;100(3):479–86. doi:10.1016/
j.ygyno.2005.08.023.
50. Cohen S, Kamarck T, Mermelstein R. A global measure of per-
ceived stress. J Heal Soc Behav. 1983;24:385–96.
51. Cohen S, Williamson G. Perceived stress in a probability sample of
the U.S. In: Oskamp SSS, editor. The social psychology of health:
Claremont Symposium on Applied Social Psychology. Newbury
Park: Sage; 1988.
52. Branstrom R, Kvillemo P, Brandberg Y, Moskowitz JT. Self-report
mindfulness as a mediator of psychological well-being in a stress
reduction intervention for cancer patients–a randomized study.
Ann Behav Med. 2010;39(2):151–61. doi:10.1007/s12160-010-
9168-6.
53. Radloff L. The CES-D scale: a self report depression scale for research
in the general population. Appl Psychol Meas. 1977;1:385–401.
54. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz
BE, Belin TR. Quality of life in long-term, disease-free survivors
of breast cancer: a follow-up study. J Natl Canc Inst. 2002;94
(1):39–49.
55. Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE. Breast
cancer in younger women: reproductive and late health effects of
treatment. J Clin Oncol. 2003;21(22):4184–93. doi:10.1200/
JCO.2003.04.196.
56. Horowitz M, Wilner N, Alvarez W. Impact of event scale: a
measure of subjective stress. PsychosomMed. 1979;41(3):209–18.
57. Andersen BL, Farrar WB, Golden-Kreutz D, Kutz LA, MacCallum
R, Courtney ME, et al. Stress and immune responses after surgical
treatment for regional breast cancer. J Natl Canc Inst. 1998;90
(1):30–6.
58. Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using
self-report assessment methods to explore facets of mindfulness.
Assessment. 2006;13(1):27–45. doi:10.1177/1073191105283504.
59. Neff KD. Development and validation of a scale to measure self-
compassion. Self Ident. 2003;2:223–50.
60. Birnie K, Garland SN, Carlson LE. Psychological benefits for
cancer patients and their partners participating in mindfulness-
based stress reduction (MBSR). Psycho Oncol. 2010;19(9):1004–
9. doi:10.1002/pon.1651.
61. Forti A. Mindfulness and quality of life among breast cancer
survivors: the mediating role of self-kindness and alexithymia.
Ph.D. thesis; 2011.
62. Henkel V, Mergl R, Kohnen R, Maier W, Moller HJ, Hegerl U.
Identifying depression in primary care: a comparison of different
methods in a prospective cohort study. BMJ. 2003;326(7382):200–
1.
63. Bech P, Olsen LR, Kjoller M, Rasmussen NK. Measuring well-
being rather than the absence of distress symptoms: a comparison
of the SF-36 Mental Health subscale and the WHO-Five Well-
Being Scale. Int J Methods Psychiatr Res. 2003;12(2):85–91.
64. Watson D, Clark LA, Tellegen A. Development and validation of
brief measures of positive and negative affect: the PANAS scales. J
Pers Soc Psychol. 1988;54(6):1063–70.
65. Watson D, Clark LA. The PANAS-X: manual for the positive and
negative affect schedule—expanded form. Iowa City: University
of Iowa; 1994.
66. Bellizzi KM, Blank TO. Cancer-related identity and positive affect
in survivors of prostate cancer. J Canc Surviv. 2007;1(1):44–8.
doi:10.1007/s11764-007-0005-2.
67. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis
using mean summary statistics and its implications for design. Stat
Med. 1992;11(13):1685–704.
68. Edwards LJ, Muller KE, Wolfinger RD, Qaqish BF, Schabenberger
O. An R2 statistic for fixed effects in the linear mixed model. Stat
Med. 2008;27(29):6137–57. doi:10.1002/sim.3429.
69. Webster K, Cella D, Yost K. The Functional Assessment of Chron-
ic Illness Therapy (FACIT) Measurement System: properties,
applications, and interpretation. Health Qual Life Outcomes.
2003;1:79. doi:10.1186/1477-7525-1-79.
70. Lengacher CA, Johnson-Mallard V, Barta M, Fitzgerald S, Moscoso
MS, Post-White J, et al. Feasibility of a mindfulness-based stress
reduction program for early-stage breast cancer survivors. J Holist
Nurs. 2011;29(2):107–17. doi:10.1177/0898010110385938.
71. Edinger JD, Olsen MK, Stechuchak KM, Means MK, Lineberger
MD, Kirby A, et al. Cognitive behavioral therapy for patients with
primary insomnia or insomnia associated predominantly with
mixed psychiatric disorders: a randomized clinical trial. Sleep.
2009;32(4):499–510.
72. Edinger JD, Wohlgemuth WK, Radtke RA, Coffman CJ, Carney
CE.Dose–response effects of cognitive-behavioral insomnia therapy:
a randomized clinical trial. Sleep. 2007;30(2):203–12.
73. Carmody J, Baer RA. How long does a mindfulness-based stress
reduction program need to be? A review of class contact hours and
effect sizes for psychological distress. J Clin Psychol. 2009;65
(6):627–38. doi:10.1002/jclp.20555.
74. Britton WB, Bootzin RR, Cousins JC, Hasler BP, Peck T, Shapiro
SL. The contribution of mindfulness practice to a multicomponent
behavioral sleep intervention following substance abuse treatment
in adolescents: a treatment-development study. Subst Abus.
2010;31(2):86–97. doi:10.1080/08897071003641297.
75. Heidenreich T, Tuin I, Pflug B, Michal M, Michalak J.
Mindfulness-based cognitive therapy for persistent insomnia: a
pilot study. Psychother Psychosom. 2006;75(3):188–9.
doi:10.1159/000091778.
76. Ong JC, Shapiro SL, Manber R. Combining mindfulness medita-
tion with cognitive-behavior therapy for insomnia: a treatment-
J Cancer Surviv (2013) 7:165–182 181
development study. Behav Ther. 2008;39(2):171–82. doi:10.1016/
j.beth.2007.07.002.
77. Ong JC, Shapiro SL, Manber R. Mindfulness meditation and
cognitive behavioral therapy for insomnia: a naturalistic 12-
month follow-up. Explore (NY). 2009;5(1):30–6. doi:10.1016/
j.explore.2008.10.004.
78. YookK, Lee SH, RyuM,KimKH, Choi TK, Suh SY, et al. Usefulness
of mindfulness-based cognitive therapy for treating insomnia in
patients with anxiety disorders: a pilot study. J Nerv Ment Dis.
2008;196(6):501–3. doi:10.1097/NMD.0b013e31817762ac.
79. Garland SN, Carlson LE, Antle MC, Samuels C, Campbell T.
I-CAN SLEEP: rationale and design of a non-inferiority RCT
of mindfulness-based stress reduction and cognitive behavioral
therapy for the treatment of insomnia in cancer survivors.
Contemp Clin Trials. 2011;32(5):747–54. doi:10.1016/
j.cct.2011.05.014.
182 J Cancer Surviv (2013) 7:165–182
